Oteseconazole

Azole Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Oteseconazole is an onp drug in the Azole Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors. DrugCentral lists 4 molecular targets, including ERG11, CYP3A4 and CYP2C19. Recorded indications include Recurrent vulvovaginal candidiasis (RVVC).

• Approval status: onp (first approved 2022 by the FDA).
• Drug class: Azole Antifungal.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors.
• Molecular targets: ERG11, CYP3A4, CYP2C19 and CYP2C9 (4 listed in DrugCentral).
• Indications: Recurrent vulvovaginal candidiasis (RVVC).
• ATC code: J02AC06 (Triazole and tetrazole derivatives).
• Molecular formula: C23H16F7N5O2; molecular weight 527.40 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Recurrent vulvovaginal candidiasis (RVVC)

Contraindications (2)

• Lactation
• Pregnancy, function

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors
• Established pharmacologic class: Azole Antifungal

Molecular targets (4)

Target	Gene	Action	Activity
Lanosterol 14-alpha demethylase	ERG11	inhibitor	Kd 7.41
Cytochrome P450 3A4	CYP3A4	inhibitor	IC50 4.19
Cytochrome P450 2C19	CYP2C19	inhibitor	IC50 4.14
Cytochrome P450 2C9	CYP2C9	inhibitor	IC50 4.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2022-04-26	FDA	—	MYCOVIA PHARMACEUTICALS INC

ATC classification

ATC code	Therapeutic hierarchy
J02AC06	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Triazole and tetrazole derivatives

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Oteseconazole is on its molecule page.

• Molecular formula: C₂₃H₁₆F₇N₅O₂
• Molecular weight: 527.40 g/mol
• CAS number: 1340593-59-0
• InChIKey: IDUYJRXRDSPPRC-NRFANRHFSA-N
• PubChem CID: 77050711

O[C@@](CN1C=NN=N1)(C1=C(F)C=C(F)C=C1)C(F)(F)C1=CC=C(C=N1)C1=CC=C(OCC(F)(F)F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Oteseconazole used for?

DrugCentral lists the following indications for Oteseconazole: Recurrent vulvovaginal candidiasis (RVVC).

How does Oteseconazole work?

Oteseconazole is classified as Breast Cancer Resistance Protein Inhibitors; its molecular targets in DrugCentral include ERG11 (inhibitor), CYP3A4 (inhibitor), CYP2C19 (inhibitor) and CYP2C9 (inhibitor).

When was Oteseconazole first approved?

Oteseconazole was first approved by the FDA in 2022.

What drug class does Oteseconazole belong to?

Oteseconazole is in the Azole Antifungal class.

What is the chemical formula of Oteseconazole?

Oteseconazole has the molecular formula C23H16F7N5O2 and a molecular weight of 527.40 g/mol.

Sources

• DrugCentral drug card 5510 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3311228 — compound record and bioactivity
• PubChem CID 77050711 — chemical identifiers
• DrugBank DB13055 — drug record
• FDA UNII VHH774W97N — substance identity
• DailyMed: FDA labels for Oteseconazole — current prescribing information (label search)
• UniProt P08684 (CYP3A4) — target protein
• UniProt P33261 (CYP2C19) — target protein
• UniProt P11712 (CYP2C9) — target protein

How this page is built: methodology · editorial policy & corrections.